Canada Spends Logo

Explore our Budget 2026 analysis

Grant: O. Gr.: Addr. the Health Impacts of COVID-19 - Imp. of def/disp care on health

University of British Columbia

$500,000.00

COVID-19 And Severe Community-Acquired Pneumonia Dynamic Evaluation Study (CASCADES - ARBS CORONA III)

FY 2021-22

Summary
Bacterial community-acquired pneumonia (CAP) is a common complication of chronic heart, kidney, lung diseases and diabetes. During the COVID-19 pandemic (2020-present), changes to health care access could have increased the occurrence and death rate of CAP especially in patients with chronic heart, kidney, lung disease and diabetes. COVID-19 could increase occurrence of CAP because of over-crowding during lockdown, less frequent physician visits and thus inadequate treatment of underlying diseases, and increased alcohol and drug use (both risk factors for CAP). We chose to study effects of COVID-19 on CAP because (1) CAP is similar to COVID-19 (characteristics, treatments, and requirement for hospital and ICU admission) and (2) CAP patients may be disadvantaged during COVID-19 waves (e.g. decreased pneumococcal vaccine use, sub-optimal treatment of CAP and limited ICU bed availability). Because of changes to the frequency of CAP, patient characteristics, adherence to treatment guidelines, treatment, and ICU bed availability, we believe that the death rate of CAP patients increased during COVID-19 compared to pre-COVID-19 (2018-2019). To understand how COVID-19 has impacted CAP mortality, we will compare the number of CAP cases during the pre-COVID-19 period and during COVID-19 in sites across Canada. We will analyze the baseline characteristics, treatment, adherence to treatment guidelines to understand what changes occurred and whether these changes increased mortality of CAP. This study is a natural extension of our well established and funded ARBs CORONA program with experts in epidemiology, COVID-19, CAP, sepsis, heart, kidney and lung disease, public health, microbiology, and trials. Our study could drive changes in CAP management:(1) increased pneumococcal and H. influenza vaccine programs, (2) enhanced earlier CAP diagnosis, (3) CAP screening protocols in emergency departments, and (4) greater adherence to CAP treatment guidelines.
Program
O. Gr.: Addr. the Health Impacts of COVID-19 - Imp. of def/disp care on health
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
460253
Name
Russell James A
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
Operating Grant : Addressing the Wider Health Impacts of COVID-
Projecttitle
COVID-19 And Severe Community-Acquired Pneumonia Dynamic Evaluation Study (CASCADES - ARBS CORONA III)
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$500,000
Cihrequipment2
$0
Programname2
O. Gr.: Addr. the Health Impacts of COVID-19 - Imp. of def/disp care on health
Keyworddelim
Bacterial Community-Acquired Pneumonia; Chronic Kidney Disease; Chronic Obstructive Pulmonary Disease; Covid-19; Individuals Experiencing Homelessness; Ras Pathway; Sepsis
Abstract
Bacterial community-acquired pneumonia (CAP) is a common complication of chronic heart, kidney, lung diseases and diabetes. During the COVID-19 pandemic (2020-present), changes to health care access could have increased the occurrence and death rate of CAP especially in patients with chronic heart, kidney, lung disease and diabetes. COVID-19 could increase occurrence of CAP because of over-crowding during lockdown, less frequent physician visits and thus inadequate treatment of underlying diseases, and increased alcohol and drug use (both risk factors for CAP). We chose to study effects of COVID-19 on CAP because (1) CAP is similar to COVID-19 (characteristics, treatments, and requirement for hospital and ICU admission) and (2) CAP patients may be disadvantaged during COVID-19 waves (e.g. decreased pneumococcal vaccine use, sub-optimal treatment of CAP and limited ICU bed availability). Because of changes to the frequency of CAP, patient characteristics, adherence to treatment guidelines, treatment, and ICU bed availability, we believe that the death rate of CAP patients increased during COVID-19 compared to pre-COVID-19 (2018-2019). To understand how COVID-19 has impacted CAP mortality, we will compare the number of CAP cases during the pre-COVID-19 period and during COVID-19 in sites across Canada. We will analyze the baseline characteristics, treatment, adherence to treatment guidelines to understand what changes occurred and whether these changes increased mortality of CAP. This study is a natural extension of our well established and funded ARBs CORONA program with experts in epidemiology, COVID-19, CAP, sepsis, heart, kidney and lung disease, public health, microbiology, and trials. Our study could drive changes in CAP management:(1) increased pneumococcal and H. influenza vaccine programs, (2) enhanced earlier CAP diagnosis, (3) CAP screening protocols in emergency departments, and (4) greater adherence to CAP treatment guidelines.
Competitiondate
202111
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Russell, James A
Approvedterm
2 ans 0 mois
Cihrcontribution2
HIV/AIDS~ $500,000~ $0~